Helixmith Co., Ltd.

This early-stage trial tested whether an experimental drug called Engensis (VM202) is safe when injected into the leg muscles of people with Charcot-Marie-Tooth disease type 1A (CMT1A), a genetic nerve disorder that causes muscle weakness. Twelve adults with mild to moderate CMT1…

This early-stage study tested whether a gene medicine called VM202 is safe to inject directly into heart muscle areas that couldn't be fully fixed during bypass surgery. Nine adults with ischemic heart disease took part. The main goal was to check for side effects over six months…

This study tested a gene therapy called VM202 (Engensis) in 52 people with critical limb ischemia, a severe blockage of leg arteries causing pain and risk of amputation. Participants received injections into the calf muscle to see if it safely improves blood flow and reduces pain…

This study looked at the long-term safety of a drug called Engensis (VM202) for people with painful diabetic peripheral neuropathy. It followed 101 adults who had already received Engensis or a placebo in an earlier study. The main goal was to see if the drug remained safe over 6…

This study tested whether a drug called engensis is safe for people with amyotrophic lateral sclerosis (ALS), a disease that weakens muscles over time. Eighteen adults with limb-onset ALS received either engensis or a placebo injection. The main goal was to check for side effects…

This study tested a new medicine called Engensis (VM202) to see if it safely reduces pain in people with diabetic nerve damage. 104 adults with type 1 or type 2 diabetes and leg pain for at least 6 months took part. Researchers compared the change in average daily pain over 6 mon…

This study tested a medicine called Engensis to see if it can reduce pain in people with diabetic nerve damage in their feet and lower legs. 162 adults with type 1 or 2 diabetes took part. The treatment was given as a shot into the muscle and compared to a placebo (fake treatment…

This study looked at whether a medicine called Engensis can safely reduce pain in the feet and legs of people with diabetes-related nerve damage. It included 106 adults who had already completed a previous study. Researchers measured pain levels over 6 to 12 months to see if the …

This study tested whether an experimental gene therapy called VM202 could safely reduce pain in people with diabetic peripheral neuropathy. Over 500 adults with type 1 or type 2 diabetes received either VM202 injections or a placebo in their legs. The main goal was to see if the …